Determination of irinotecan, SN-38 and SN-38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients-Reference-Cited by-同舟云学术

Determination of irinotecan, SN-38 and SN-38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients

Published:2017-04-10 Issue:1 Volume:32 Page:e22217
ISSN:0887-8013
Container-title:Journal of Clinical Laboratory Analysis
language:en
Short-container-title:J Clin Lab Anal

Author:

Atasilp Chalirmporn¹²,Chansriwong Pichai³,Sirachainan Ekapob³,Reungwetwattana Thanyanan³,Puangpetch Apichaya¹²,Prommas Santirhat¹²,Sirilerttrakul Suwannee³,Rerkarmnuaychoke Budsaba⁴,Wongwaisayawan Sansanee⁵,Sukasem Chonlaphat¹²^ORCID

Affiliation:

1. Division of Pharmacogenomics and Personalized Medicine; Department of Pathology; Faculty of Medicine Ramathibodi Hospital; Mahidol University; Bangkok Thailand

2. Laboratory for Pharmacogenomics, Clinical Pathology; Somdetch Phra Debharatana Medical Centre; Ramathibodi Hospital; Bangkok Thailand

3. Division of Medical Oncology; Department of Medicine; Faculty of Medicine Ramathibodi Hospital; Mahidol University; Bangkok Thailand

4. Division of Human Genetics Laboratory; Department of Pathology; Faculty of Medicine Ramathibodi Hospital; Mahidol University; Bangkok Thailand

5. Division of Anatomical Pathology; Department of Pathology; Faculty of Medicine Ramathibodi Hospital; Mahidol University; Bangkok Thailand

Funder

Ramathibodi Hospital Cancer Center, Bangkok, Thailand

Publisher

Wiley

Subject

Microbiology (medical),Biochemistry (medical),Medical Laboratory Technology,Clinical Biochemistry,Public Health, Environmental and Occupational Health,Hematology,Immunology and Allergy

Reference20 articles.

1. Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults;Achenbach;Future Virol,2011

2. Review of biomarkers in colorectal cancer;Newton;Colorectal Dis,2012

3. Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity;Di Paolo;Curr Drug Metab,2011

4. Phase I and pharmacokinetic trial of weekly CPT-11;Rothenberg;J Clin Oncol,1993

5. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11);Mathijssen;Clin Cancer Res,2001

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial;Nature Communications;2024-08-07

2. Generation of anti-SN38 antibody for loading efficacy and therapeutic monitoring of SN38-containing therapeutics;Heliyon;2024-06

3. A validated high‐performance liquid chromatography‐tandem mass spectrometry method for simultaneous determination of irinotecan and two major metabolites in rat plasma: Application for the pharmacokinetics study;SEPARATION SCIENCE PLUS;2024-05-10

4. Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) methods for the therapeutic drug monitoring of cytotoxic anticancer drugs: An update;Journal of Chromatography B;2024-04

5. Development and validation of an UPLC-MS/MS method for the determination of irinotecan (CPT-11), SN-38 and SN-38 glucuronide in human plasma and peritoneal tumor tissue from patients with peritoneal carcinomatosis;Journal of Chromatography B;2024-02